Schrödinger Unveils New Preclinical Data on Cancer Inhibitors at ENA 2024

Schrödinger Presents New Preclinical Data on SGR-3515 and PRMT5-MTA Inhibitors at ENA 2024

Barcelona, Spain, October 23-25, 2024 – Schrödinger (NASDAQ: SDGR), a leader in computational drug discovery, has announced the presentation of new preclinical data at the 36th EORTC-NCI-AACR Symposium (ENA 2024). The company will showcase its investigational Wee1/Myt1 inhibitor, SGR-3515, and advancements in its PRMT5-MTA inhibitor program, highlighting their potential in cancer treatment.

SGR-3515: A Promising Wee1/Myt1 Inhibitor

The presentation on SGR-3515 will provide insights into its differentiated pharmacological properties observed in preclinical oncology models. Wee1 and Myt1 kinases are crucial for regulating the cell cycle and DNA damage response, facilitating DNA repair before cell division. The inhibition of these kinases can induce synthetic lethality, selectively targeting cancer cells. Preclinical findings suggest SGR-3515 holds promise as a therapy for advanced solid tumors, with an ongoing Phase 1 clinical trial.

PRMT5-MTA Inhibitors: Targeting MTAP-deficient Tumors

Schrödinger will also present data on its selective PRMT5-MTA inhibitors, discovered through advanced virtual screening technology. This novel series of inhibitors is being optimized for treating both peripheral and brain tumors, particularly those deficient in MTAP.

Presentation Details

• Title: Discovery of SGR-3515, a first-in-class Wee1/Myt1 inhibitor with differentiated pharmacological properties in xenograft tumor models

  • Abstract Number: 147
  • Date & Time: Wednesday, October 23, 2024, 12PM-2PM CEST
  • Location: Exhibit Hall, Barcelona International Convention Centre

• Title: Discovery of a highly MTA-synergistic series of PRMT5 inhibitors for the treatment of MTAP-deficient tumors by virtual screening technology

  • Abstract Number: 372
  • Date & Time: Friday, October 25, 2024, 9AM-3PM CEST
  • Location: Exhibit Hall, Barcelona International Convention Centre

About Schrödinger

Schrödinger is at the forefront of transforming therapeutic and material discovery through its physics-based computational platform. This platform accelerates the discovery of high-quality molecules for drug development and materials applications, offering a cost-effective alternative to traditional methods. Schrödinger collaborates globally with biopharmaceutical companies, academic institutions, and government laboratories to address unmet medical needs.

Founded in 1990, Schrödinger employs approximately 850 people and serves customers in over 70 countries. For more information, visit www.schrodinger.com, follow on LinkedIn, or explore their blog at Extrapolations.com.

Cautionary Note on Forward-Looking Statements

This announcement includes forward-looking statements regarding Schrödinger's computational platform, the potential of Wee1/Myt1 and PRMT5-MTA inhibitors, and the ongoing clinical development of SGR-3515. These statements are subject to risks and uncertainties that may cause actual results to differ materially. For further details, refer to Schrödinger’s filings with the Securities and Exchange Commission.